Patients diagnosed with symptomatic obstructive hypertrophic cardiomyopathy (HCM) who are treated with aficamten have achieved significant improvement in peak oxygen compared with patients treated with a placebo. Researchers… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
